Trial Profile
Safety, Tolerability and Pharmacokinetics of Single Rising Doses of 0.5 mug, 2.5 mug, 5 mug, 10 mug, 15 mug, 20 mug, 25 mug and 30 mug BI 1744 CL (Calculated as Free Base) Given as Intravenous Infusion Over 30 Minutes to Healthy Male Subjects. A Single-centre, Single-blind, Placebo-controlled, Randomised Study.
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Olodaterol (Primary)
- Indications Asthma; Chronic obstructive pulmonary disease
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 01 Jul 2014 New trial record